U.S. markets open in 34 minutes

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1249-0.0092 (-6.86%)
At close: 03:40PM EST

Tetra Bio-Pharma Inc.

2316 St. Joseph Boulevard
Orléans, ON K1C 1E8
343 780 2020

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Guy Chamberland M.Sc., Master Herbal, Ph.D.Co-Founder, CEO, Chief Regulatory Officer & Director350.69kN/A1962
Mr. Steeve NéronChief Commercial Officer142.23kN/AN/A
Mr. André Rancourt B.Sc.Co-FounderN/AN/AN/A
Dr. Melanie Edna Mary Kelly Ph.D.Chief Scientific OfficerN/AN/AN/A
Jennifer McCaugheyVP of Investor RelationsN/AN/AN/A
Ms. Dania Scott B.Sc.Sr. VP of Commercial StrategyN/AN/AN/A
Ms. Aurelia De PauwSr. VP of Clinical Programs & Medical AffairsN/AN/AN/A
Mr. Richard GiguereChief Exec. Officer of Tetra Natural Health Inc.N/AN/AN/A
Randy RinguetteProject Director & Member of Advisory BoardN/AN/AN/A
Mr. Chris MacLeanChief Operating Officer of Tetra Natural HealthN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. It develops ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; Reduvo for chemotherapy-induced nausea and vomiting; PLENITUDE to treat advanced uncontrolled cancer pain; REBORN for the treatment of breakthrough cancer pain and fibromyalgia; and SERENITY to treat cancer cachexia. The company also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. is headquartered in Orleans, Canada.

Corporate Governance

Tetra Bio-Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.